logo
Ghana's Naomi Oyoe Ohene Oti Wins Aster Guardians Global Nursing Award 2025 Worth USD 250,000

Ghana's Naomi Oyoe Ohene Oti Wins Aster Guardians Global Nursing Award 2025 Worth USD 250,000

Business Upturn28-05-2025
Dubai, United Arab Emirates:
Nurse Naomi Ohene Oti from Ghana has been named the winner of the Aster Guardians Global Nursing Award 2025, selected from 100,000 applications from 199 countries. An Oncology Nurse Specialist and Head of Nursing at the National Radiotherapy Oncology and Nuclear Medicine Centre, Korle-Bu Teaching Hospital, she was recognised with USD 250,000 at a prestigious ceremony held in Dubai, UAE.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527165925/en/
Nurse Naomi Oyoe Ohene Oti from Ghana – Winner of Aster Guardians Global Nursing Award 2025 (Photo: AETOSWire)
The Aster Guardians Global Nursing Award was launched in 2021 to recognize the invaluable role of nurses in healthcare. The award was presented by His Excellency Sheikh Nahyan bin Mabarak Al Nahyan, Minister of Tolerance and Coexistence, UAE in presence of Dr Azad Moopen and Alisha Moopen. During this year's ceremony, Dr. Tedros Adhanom Ghebreyesus, Director-General of the WHO, shared a special message applauding Aster's effort in putting a spotlight on the contributions of nurses worldwide.
Nurse Naomi Ohene Oti said, 'For over two decades, I've witnessed the inequities in cancer care firsthand and dedicated myself to closing these gaps through training, outreach, and system-level change. This award will help amplify our impact – scaling training, building faculty, and inspiring the next generation of oncology nurses across Africa.'
Dr. Azad Moopen, Founder Chaiman, Aster DM Healthcare stated, 'Nurse Naomi Ohene Oti has redefined what it means to be a nurse – not just as a caregiver but as an innovator, leader, and changemaker. Her contributions uplift not only patients but the entire healthcare ecosystem, setting a gold standard for others to follow.
Alisha Moopen, Managing Director and Group CEO, Aster DM Healthcare added, 'Naomi Ohene Oti's story is a powerful reminder of the quiet heroism that unfolds every day in hospitals, clinics, and communities across the world. We are incredibly proud to shine a global spotlight on her work, and through her, honour the millions of nurses who keep healthcare systems running and humanity thriving.'
About Aster DM Healthcare:
Founded in 1987 by Dr. Azad Moopen, Aster DM Healthcare is a leading integrated healthcare provider, with a strong presence across seven countries. Aster is committed to the vision of providing accessible and high-quality healthcare, from primary to quaternary services, with its promise of 'We will treat you well'.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250527165925/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Xspray Pharma Submits XS003 to the FDA – The Company's Second Product Candidate from the HyNap Platform
Xspray Pharma Submits XS003 to the FDA – The Company's Second Product Candidate from the HyNap Platform

Business Wire

time2 hours ago

  • Business Wire

Xspray Pharma Submits XS003 to the FDA – The Company's Second Product Candidate from the HyNap Platform

STOCKHOLM--(BUSINESS WIRE)-- Xspray Pharma (Nasdaq Stockholm: XSPRAY) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate XS003 (nilotinib) for the treatment of chronic myeloid leukemia (CML). The application is based on successful studies demonstrating bioequivalence with the reference product Tasigna®. XS003 demonstrates the lowest documented food interaction within the nilotinib class and improved dose linearity, which gives physicians greater predictability when adjusting the dose, enabling more consistent exposure and potentially reducing the risk of side effects. Due to XS003's improved food interaction profile, the warning about three hours of fasting, currently included in the reference product's so-called boxed warning, is not expected to apply to XS003. This may simplify treatment and improve adherence. XS003 is an improved formulation of nilotinib (Tasigna®) and developed using the company's proprietary HyNap™ technology. 'Patients with chronic leukemia live not only with their disease—but also with side effects from medications, often related to food interaction and concomitant treatments. Our proprietary HyNap technology addresses these challenges and may help improve treatment outcomes and quality of life for this patient group. Our goal is to develop and commercialize a portfolio of next-generation Protein Kinase Inhibitor products with stable absorption, low variability, and minimal food interaction. With XS003, we now have two product candidates under FDA review with strong clinical potential, addressing a total U.S. market worth USD 2.7 billion,' says Per Andersson, CEO of Xspray Pharma. Data from registration studies demonstrate bioequivalence with the reference product, despite XS003 being administered at less than half the dose of the reference product. In addition, the studies confirm clearly improved dose linearity, which may provide physicians with better predictability when adjusting doses, and thereby a greater ability to achieve improved treatment outcomes. The uptake of XS003 is only slightly affected when taken with food, while the reference product is significantly affected as reflected in their label (28% vs. 82%). This may indicate improved control and a lower risk of side effects when taken with food. Xspray expects the FDA to initiate its review within 60 days, with a regulatory decision anticipated approximately eight months thereafter. Global 2024 nilotinib sales reached USD 1.67 billion in 2024, of which USD 850 million came from the U.S. About Xspray Pharma Xspray Pharma AB (publ) is a pharmaceutical company focused on the development of improved PKIs for cancer treatment, leveraging its proprietary HyNap™ technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Xspray Pharma's shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). For more information about Xspray Pharma AB and its innovative approach to cancer treatment, please visit

Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer
Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer

Business Wire

timea day ago

  • Business Wire

Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer

SÖDERTÄLJE, Sweden--(BUSINESS WIRE)--Anocca AB ('Anocca' or the 'Company'), a leading clinical-stage T-cell immunotherapy company, has successfully raised SEK ~440 million (USD ~46 million) in financing. The additional capital will be used to drive the continued progress of VIDAR-1, Anocca's gene-edited TCR-T cell therapies targeting mutant KRAS in pancreatic cancer, through early-stage clinical development, as well as progress Anocca's preclinical pipeline. The financing was led by Mellby Gård with strong support from AMF, Ramsbury and existing shareholders, alongside new investors. Recruitment is now open for Phase I of the multi-centre trial of VIDAR-1, which is being conducted at leading university hospitals across Sweden, Denmark, Germany and The Netherlands. Reagan Jarvis, co-founder and Chief Executive Officer of Anocca, said: 'We thank our investors for their strong and continued support as we advance our first TCR-T cell therapy products into the clinic. The team has built a unique discovery platform and in-house manufacturing capability, and we are now excited to see the first products reaching patients with high unmet need.' Johan Andersson, Chairman of Mellby Gård, commented: 'We have been invested in Anocca throughout its preclinical development and are pleased to see the Company transition into a clinical stage biotech. We look forward to seeing Anocca help patients that have limited treatment options today with their innovative approach to T-cell therapies.' SEB Corporate Finance acted as financial advisor to Anocca on the finalisation of the transaction, and Mannheimer Swartling and HWF Advokater have acted as legal advisors. ENDS About Anocca Anocca is a fully integrated clinical-stage biopharmaceutical company that develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. The company has built a unique discovery engine that uses programmable human cells to recreate and manipulate T cell immunity. These proprietary technologies enable scaling of TCR-T cell therapy development, allowing the systematic generation of libraries of products that represent personalised treatments for the broad patient populations. Anocca currently has the broadest pipeline of TCR-T oncology cell therapy treatments. Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and an in-house cGMP manufacturing and process development facility. Anocca's TCR-T cell therapies are novel discoveries from its platform and manufactured using non-viral gene editing technology at Anocca's facilities in Södertälje, Sweden. 130+ staff from 40+ nations work at Anocca. About the VIDAR-1 clinical programme VIDAR-1 is designed as a multi-product umbrella trial targeting oncogenic driver mutations in KRAS within pancreatic ductal adenocarcinoma (PDAC). It will investigate up to 20 patients per product in a set of phase I/II studies. Phase I is currently conducted at eight sites in four countries with additional countries and sites in phase II. Patients will be eligible to enrol if they have an HLA, and KRAS mutation, matching an available product. More information about the clinical trial can be found at the EU's clinical trials website. About KRAS and PDAC Mutant KRAS is implicated in pancreatic, lung and colorectal cancers. G12V and G12D mutations in KRAS affect around 90% of pancreatic cancer patients. The five-year survival rate of patients with PDAC is less than 10% (1). Despite recent advances there are no definitive treatments for advanced patients at present (2). References 1. Rawla et al (2019). Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 10(1):10–27. doi: 10.14740/wjon1166 2. Hu & O'Reilly (2023). Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol 21, 7–24. doi: 10.1038/s41575-023-00840-w

Kwality Pharma receives product registration for Bleomycin 15 IU per vial in Mexico
Kwality Pharma receives product registration for Bleomycin 15 IU per vial in Mexico

Business Upturn

timea day ago

  • Business Upturn

Kwality Pharma receives product registration for Bleomycin 15 IU per vial in Mexico

Kwality Pharmaceuticals Ltd has announced that it has received registration approval for Bleomycin 15 IU in Mexico, enabling the company to begin sales and distribution in the region. Bleomycin is a widely prescribed oncology medicine, used in the treatment of Hodgkin's lymphoma, testicular cancer, and certain squamous cell carcinomas. The approval marks a significant milestone in Kwality Pharmaceuticals' strategy to expand into highly regulated international markets. With this registration, the company is further reinforcing its global footprint in the oncology segment, offering patients access to advanced and affordable cancer treatments. According to the company, the business potential in Mexico is projected to be around USD 1 million in the first year, with supplies scheduled to commence before the end of Q2 FY26. Highlighting its commitment, Kwality Pharmaceuticals stated that it will continue to expand its oncology portfolio across international markets to make high-quality medicines more accessible worldwide. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store